The Effect of Continuous Intravenous Infusion of Lidocaine on PPCs and Prognosis in Emergency Surgical Patients With IAI

NAActive, not recruitingINTERVENTIONAL
Enrollment

428

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

June 30, 2026

Conditions
Postoperative Pulmonary ComplicationsIntra-abdominal Infection
Interventions
DRUG

Lidocaine

"Lidocaine group receive a loading dose of 1.5 mg/kg 2% lidocaine at anesthesia induction, followed by continuous intravenous infusion at 1.5 mg/kg/h until 24 hours postoperatively and Control group receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively.~Both groups will receive the same anesthesia and postoperative analgesia protocols, lung-protective ventilation strategy, and fluid, transfusion, and warming strategies. The only difference is the intervention during surgery, with the lidocaine group receiving continuous intravenous lidocaine."

DRUG

Placebo

atients receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively.

Trial Locations (1)

200032

Zhongshan Hospital,Fudan university, Shanghai

All Listed Sponsors
collaborator

Tianjin Medical University General Hospital

OTHER

collaborator

The Affiliated Hospital of Xuzhou Medical University

OTHER

collaborator

West China Hospital

OTHER

lead

Shanghai Zhongshan Hospital

OTHER

NCT06304779 - The Effect of Continuous Intravenous Infusion of Lidocaine on PPCs and Prognosis in Emergency Surgical Patients With IAI | Biotech Hunter | Biotech Hunter